Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease.
Thirty-five individuals from endemic areas of Central Brazil (age range, 18-64 years; 19 women) in the chronic phase of Chagas disease, with positive serology and presence of circulating parasites detected by one or more recent positive xenodiagnosis, were selected for this study. Allopurinol (900 mg/d) or placebo was administered in a double-blind clinical trial for 60 days. After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group. Side effects were observed in 11 patients in the intervention group and in 1 in the placebo group. Seventeen patients in the intervention group and 10 in the placebo group completed the trial. Follow-up was performed by monthly xenodiagnosis and serologic tests every 3 months during the first year and at the end of the trial. Xenodiagnosis remained positive in all 17 of the treated group and in all 10 of the placebo group. Serologic tests were persistently positive in both groups after treatment. We concluded that, at the doses used, allopurinol was not effective to clear, in our region, Trypanosoma cruzi from peripheral blood of infected individuals.
Rassi
Anis
A
Anis Rassi Hospital, Goiânia, Brazil.
Luquetti
Alejandro Ostermayer
AO
Rassi
Anis
A
Rassi
Gustavo Gabriel
GG
Rassi
Sergio Gabriel
SG
DA Silva
Ionizete Garcia
IG
Rassi
Alexandre Gabriel
AG
D000293:Adolescent; D000328:Adult; D000493:Allopurinol / Q000627:therapeutic use*; D000818:Animals; D000977:Antiparasitic Agents / Q000627:therapeutic use*; D014355:Chagas Disease / Q000188:drug therapy*; D002908:Chronic Disease / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure; D014349:Trypanosoma cruzi / Q000187:drug effects*
D000977:Antiparasitic Agents; D000493:Allopurinol